Group 1 - Viatris Inc. will report its second quarter 2025 financial results on August 7, 2025, with a webcast scheduled for 8:30 a.m. ET to discuss the results [1] - The company invites investors and the general public to listen to the live webcast, which can be accessed via their investor website or through designated phone numbers [1] - A replay of the webcast will also be available on the company's website [1] Group 2 - Viatris Inc. is a global healthcare company that combines generics and brand medicines to address healthcare needs worldwide [2] - The company aims to empower people to live healthier lives, providing access to high-quality medicines for approximately 1 billion patients annually [2] - Viatris has a diverse portfolio of medicines and a unique global supply chain, with headquarters in the U.S. and global centers in Pittsburgh, Shanghai, and Hyderabad [2]

Company Overview - Viatris Inc. is currently experiencing strong performance in its base business, with 8 to 9 consecutive quarters of operational revenue growth despite some manufacturing issues at a specific plant [2][3] - The company has exceeded initial guidance for total new product revenue in the previous year, indicating effective execution of its product strategy [2] Financial Performance - Viatris has been actively engaging in capital allocation strategies, including paying dividends and share buybacks, with over $300 million spent on share repurchases to date [3]

Summary of Viatris (VTRS) FY Conference Call - June 09, 2025 Company Overview - **Company**: Viatris (VTRS) - **Key Executives Present**: Scott Smith (CEO), Doretta Mistras (CFO), Corinne Lagoff (CCO), Philippe Martin (Head of R&D) [2][3] Core Industry Insights - **Industry**: Pharmaceutical and Biotechnology - **Market Dynamics**: Viatris operates in a competitive landscape with a focus on both branded (60%) and generic (40%) products, with a significant portion of branded products being past loss of exclusivity (LOE) [11][12] Key Points and Arguments 1. **Base Business Performance**: The base business is described as strong, with eight to nine consecutive quarters of operational revenue growth, despite some manufacturing issues at the Indoor plant [4][6] 2. **Capital Allocation Strategy**: Viatris has been actively buying back shares, totaling over $300 million, while also focusing on dividends and business development [5][63] 3. **Pipeline Development**: The company has a robust pipeline with 11 programs in Phase III, all showing positive results, including products for anxiety, pain, and eye care [6][10] 4. **Strategic Review**: An enterprise-wide strategic review is underway to optimize operations and ensure the right personnel are in place for future growth [7][9] 5. **FDA Resubmission**: The Indoor facility is on track for FDA re-inspection mid-year, with remediation efforts progressing ahead of schedule [8][32] 6. **Tariff Concerns**: Potential pharmaceutical tariffs could impact the generic market significantly, with 90% of dispensed products being generics, yet only accounting for 1% of total healthcare costs [19][22] 7. **Impact of Legislation**: The company has limited exposure to recent legislative changes, as 99% of its portfolio has gone through LOE, indicating minimal current impact but potential future considerations [30][31] 8. **Acute Pain Market Opportunity**: Viatris is developing a fast-acting meloxicam for acute pain, targeting a market of 70-80 million cases annually, with a significant unmet need for non-opioid treatments [43][44] 9. **Ocular Portfolio**: The company is expanding its eye care division, with recent positive Phase III data for a product addressing dim light disturbances post-surgery, indicating a potential first FDA-approved treatment for this condition [72][74] Additional Important Insights - **Market Size**: The acute pain market in the U.S. is valued at approximately $44 billion, highlighting the significant revenue potential for Viatris's new product [46] - **Patient Education**: For the emergency therapeutic option for heart attacks, Viatris is focusing on patient education to ensure timely self-administration of the treatment [60][61] - **Future Growth**: The company aims for sustainable revenue and EBITDA growth in 2026 and beyond, with a focus on innovative products and capital allocation strategies [10][12] This summary encapsulates the key themes and insights from the Viatris FY Conference Call, providing a comprehensive overview of the company's current status, strategic direction, and market opportunities.

Company Overview - Viatris Inc. is actively participating in the Jefferies Global Healthcare Conference, with key executives including the Chief Financial Officer and Chief Commercial Officer present to discuss the company's performance and strategy [1]. Macro and Regulatory Environment - The CFO of Viatris acknowledges the evolving and dynamic market conditions, particularly in the generics sector, and emphasizes the importance of execution in the current year [2]. Financial Performance - Viatris reported solid first-quarter earnings, with sales meeting expectations across all segments, particularly noting operational growth in China and Europe. Excluding the impact from divestitures, the company achieved approximately 2% growth on a divestiture-adjusted operational basis [3].

Core Viewpoint - Class action lawsuits have been filed against Viatris Inc. and Canopy Growth Corporation, alleging that both companies made materially false and misleading statements regarding their business operations and financial prospects during specified class periods [2][3]. Viatris Inc. (NASDAQ: VTRS) - Class Period: August 8, 2024 – February 26, 2025 - Lead Plaintiff Deadline: June 3, 2025 - Allegations include failure to disclose the significant impact of a failed FDA inspection at the Indore facility, which affected the company's ability to manufacture and ship key products, particularly Lenalidomide [2]. - The complaint states that the positive statements made by the defendants regarding the company's business were materially misleading and lacked a reasonable basis [2]. Canopy Growth Corporation (NASDAQ: CGC) - Class Period: May 30, 2024 – February 6, 2025 - Lead Plaintiff Deadline: June 3, 2025 - Allegations include incurring significant costs related to the production of Claybourne pre-rolled joints and the Storz & Bickel vaporizer devices, which negatively impacted the company's gross margins and overall financial results [3]. - The complaint asserts that the defendants overstated the efficacy of cost reduction measures and downplayed issues affecting gross margins, leading to materially misleading statements about the company's business [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth projections [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Viatris [2]. - The complaint alleges that Viatris and its executives made false statements and failed to disclose significant risks related to a failed FDA inspection at its Indore facility, which adversely affected the company's financial outlook [4]. - The class action lawsuit claims that Viatris downplayed the impact of the FDA inspection and the resulting remediation efforts, which significantly hindered the company's ability to manufacture and ship key products [4]. Group 2: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for Q4 and full fiscal year 2024, attributing below-expectation guidance to the financial impact from the Indore facility's warning letter and import alert [5]. - Following the announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [6].

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the impact of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. FDA, leading to a significant drop in stock price following the announcement of disappointing financial results [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, supplying medicines to 1 billion patients globally [2]. Legal Proceedings - The lawsuit covers purchasers of Viatris securities from August 8, 2024, to February 26, 2025, and investors have until June 3, 2025, to seek appointment as lead plaintiff [1][2]. - The lawsuit claims that Viatris downplayed the consequences of regulatory issues, which were revealed when the company announced its Q4 and full-year 2024 financial results, resulting in a stock price decline of over 15% [3]. Financial Impact - Following the announcement on February 27, 2025, Viatris' stock price fell from $11.24 to $9.53 per share, a decrease of $1.71 per share [3].

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, captioned Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the inspection's repercussions would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must move the Court by June 3, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that would prevent shipping eleven products [4] - Defendants allegedly downplayed the impact of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection and remediation efforts [5] - The misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true information became public [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must move the Court by June 3, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that would prevent shipping eleven products [4] - Defendants allegedly made materially false statements and concealed adverse facts about the impact of the warning letter on Viatris' financials, leading to artificially inflated security prices [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the inflated prices at which they purchased Viatris securities [5]